Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Min Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5587-5520; OpenAlex author ID A5011037616. Sources: OpenAlex.

Their work

Papers
21 (first author 0, last author 18)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2016: 1 paper · 2017: 4 papers · 2018: 2 papers · 2019: 2 papers · 2020: 4 papers · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: 2 papers

Papers 21

  1. Correction to: Methyl-CpG-binding domain 3 inhibits epithelial-mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signalling. Co-author DOI 10.1038/s41416-025-03208-w↗
  2. [Corrigendum] Furin promotes epithelial‑mesenchymal transition in pancreatic cancer cells via Hippo‑YAP pathway. Last author DOI 10.3892/ijo.2025.5797↗
  3. LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway. Last author DOI 10.1016/j.abb.2023.109783↗
  4. LncRNA FAM83A-AS1 promotes epithelial-mesenchymal transition of pancreatic cancer cells via Hippo pathway. Last author DOI 10.1080/15384101.2023.2216507↗
  5. CTSK and PLAU as Prognostic Biomarker and Related to Immune Infiltration in Pancreatic Cancer: Evidence from Bioinformatics Analysis and qPCR. Last author DOI 10.1155/2023/3914687↗
  6. Vitamin C Sensitizes Pancreatic Cancer Cells to Erastin-Induced Ferroptosis by Activating the AMPK/Nrf2/HMOX1 Pathway. Last author DOI 10.1155/2022/5361241↗
  7. Pancreatic Cancer Cell-Derived Exosomes Promote Lymphangiogenesis by Downregulating ABHD11-AS1 Expression. Last author DOI 10.3390/cancers14194612↗
  8. The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. Last author DOI 10.1002/1878-0261.12836↗
  9. Linc-RoR promotes proliferation, migration, and invasion via the Hippo/YAP pathway in pancreatic cancer cells. Last author DOI 10.1002/jcb.29308↗
  10. Methyl-CpG-binding domain 3 inhibits stemness of pancreatic cancer cells via Hippo signaling. Last author DOI 10.1016/j.yexcr.2020.112091↗
  11. Methyl-CpG-binding protein 2 drives the Furin/TGF-β1/Smad axis to promote epithelial-mesenchymal transition in pancreatic cancer cells. Last author DOI 10.1038/s41389-020-00258-y↗
  12. PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells. Last author DOI 10.1111/jcmm.14894↗
  13. Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis. Last author DOI 10.7150/jca.32052↗
  14. The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. Last author PMID 30949406↗
  15. LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells via the Hippo pathway. Last author DOI 10.1016/j.bbadis.2018.03.005↗
  16. Long non‑coding RNA PVT1 promotes epithelial‑mesenchymal transition via the TGF‑β/Smad pathway in pancreatic cancer cells. Last author DOI 10.3892/or.2018.6462↗
  17. Methyl-CpG-binding domain 3 inhibits epithelial-mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signalling. Co-author DOI 10.1038/bjc.2016.397↗
  18. YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. Last author DOI 10.1080/15384101.2017.1380125↗
  19. The mir-675-5p regulates the progression and development of pancreatic cancer via the UBQLN1-ZEB1-mir200 axis. Last author DOI 10.18632/oncotarget.15330↗
  20. Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway. Last author DOI 10.3892/ijo.2017.3896↗
  21. MeCP2 suppresses LIN28A expression via binding to its methylated-CpG islands in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.7507↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aihua Gong · 19 shared papers, 2016–2025 · strength 2.21
  2. Huizhi Wang · 8 shared papers, 2019–2023 · strength 1.17
  3. Wan‐Xin Peng · 9 shared papers, 2016–2025 · strength 1.00
  4. Youli Zhang · 10 shared papers, 2016–2025 · strength 0.99
  5. Yuntao Ding · 3 shared papers, 2023 · strength 0.61
  6. Qi Wang · 2 shared papers, 2023 · strength 0.41
  7. Yawen Liu · 2 shared papers, 2021–2022 · strength 0.28
  8. Yawen Liu · 3 shared papers, 2019–2020 · strength 0.28
  9. Lu Ge · 3 shared papers, 2016–2020 · strength 0.24
  10. Huizhi Wang · 2 shared papers, 2020–2021 · strength 0.23
  11. Jingyu Min · 2 shared papers, 2020–2021 · strength 0.22
  12. Wei Chen · 2 shared papers, 2020 · strength 0.20
  13. Meiting Zhang · 2 shared papers, 2018–2019 · strength 0.17
  14. Xulin Zhou · 1 shared paper, 2022 · strength 0.16
  15. Sihui Wu · 1 shared paper, 2022 · strength 0.16
  16. Xiangyu Kong · 1 shared paper, 2019 · strength 0.08
  17. Xingxing Zhang · 1 shared paper, 2018 · strength 0.08
  18. Yu Xia · 1 shared paper, 2017 · strength 0.07
  19. Xingxing Zhang · 1 shared paper, 2017 · strength 0.07
  20. Jue Wang · 1 shared paper, 2017 · strength 0.07
  21. Jixiang Chen · 1 shared paper, 2017 · strength 0.06
  22. Yin‐Yuan Mo · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.